Insights

Mesoblast (ASX:MSB) share price crawls higher on Q1 trading update

The Mesoblast share price is in the green today as investors respond positively to the company’s latest update.
The post Mesoblast (ASX:MSB) share price crawls higher on Q1 trading update appeared first on The Motley Fool Australia. –

The Mesoblast Ltd (ASX: MSB) share price is inching higher to start off the session today and is now trading at $1.74. That’s up 1.75%.

The regenerative medicine company’s shares are on the move after it reported its results for the first quarter ended September 30, 2021.

Here are the key takeouts from Mesoblast’s Q1 trading update.

Mesoblast share price gains on revenue and cash growth

Key investment highlights for the quarter include:

Total Revenue was US$3.6 million for the first quarter FY2022, a year on year increase of US$2.3 million
Net operating cash usage was US$19.6 million for the quarter, a reduction of US$8.6 million on the year prior
Research and Development expenses reduced by US$10.0 million, or 52%, for the Q1 FY22 from US$19.3 million for Q1 FY21
Manufacturing expense reduced by 37%, down from US$11.9 million for the first Q1 FY21
Loss after tax improved to US$22.6 million, a US$1.9 million improvement year on year
The net loss attributable to ordinary shareholders was 3.49 US cents per share, compared with 4.21 US cents the same time last year.

What happened in Q1 FY22 for Mesoblast?

The company achieved several progress points this quarter. Total revenue for Q1 was US$3.6 million, an increase of US$2.3 million on Q1 FY21.

The boost in revenue was largely driven by growth in royalties and a US$1.2 million milestone payment regarding the Alofisel product’s manufacture and marketing in Japan.

In addition, royalty income from its Temcell HS segment in Japan was US$2.4 million, an increase of 22% on the previous quarter, and of 90% on Q1 FY21.

To secure cash, Mesoblast successfully entered into the refinancing and expansion of a senior debt facility with Oaktree Capital Management.

The new US$90 million, 5-year secured facility has a 3-year interest-only period and matures in November 2026.

As a result of the new debt, and other borrowing arrangements, finance costs were US$3.6 million for the quarter, compared to US$2.9 million for the year prior.

Even still, net cash operating usage was US$19.6 million for the quarter, a reduction of US$8.6 million year on year. As a result, the company’s after-tax loss improved by US$1.9 million on the same period in FY21 to US$22.6 million.

Mesoblast also made progress on developing its drug candidates this quarter. The company is in talks with the US Federal Drug Administration (FDA) on how to get its rexlemestrocel-L candidate approved for use in “heart failure patients at high risk of cardiovascular mortality, heart attacks or strokes”.

Manufacturing expense also reduced by 37% to US$7.5 million due to a reduction in “process development activities”. During the quarter, Mesoblast also continued to build its “pre-launch inventory levels of remestemcel-L to support the long-term commercial supply for SR-aGVHD and COVID ARDS”.

What did management say?

Speaking on the announcement, Mesoblasts’s CEO Silviu Itescu said:

We are pleased to have entered into a strategic financing partnership with leading global investment management firm Oaktree Capital as we focus on bringing our first product to the US market and in line with our commercial growth strategy over the next five years.

In the past 12 months, the Mesoblast share price has lost more than 61%, falling 22% this year to date.

The post Mesoblast (ASX:MSB) share price crawls higher on Q1 trading update appeared first on The Motley Fool Australia.

Should you invest $1,000 in Mesoblast right now?

Before you consider Mesoblast, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

These are the 10 most shorted ASX shares

Mesoblast (ASX:MSB) share price tumbles 8% giving back most of yesterday’s gains

Why Best & Less, BHP, Mesoblast, and Nearmap shares are falling

ASX 200 (ASX:XJO) midday update: Telstra investor day, tech and materials shares fall

Why Cardno, Incitec Pivot, Mesoblast, and WiseTech are storming higher

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!